› 6o39

X-ray diffraction
1.8Å resolution

Crystal structure of Frizzled 5 CRD in complex with F2.I Fab

Released:
DOI: 10.2210/pdb6o39/pdb
Model geometry
Fit model/data
PDB entry 6o39 coloured by chain, front view.
PDB entry 6o39 coloured by chain, side view.
PDB entry 6o39 coloured by chain, top view.
Source organism: Homo sapiens
Primary publication:
Structure-guided design fine-tunes pharmacokinetics, tolerability, and antitumor profile of multispecific frizzled antibodies.
Raman S, Beilschmidt M, To M, Lin K, Lui F, Jmeian Y, Ng M, Fernandez M, Fu Y, Mascall K, Duque A, Wang X, Pan G, Angers S, Moffat J, Sidhu SS, Magram J, Sinclair AM, Fransson J, Julien JP
Proc Natl Acad Sci U S A 116 6812-6817 (2019)
PMID: 30894493

Function and Biology Details

Biochemical function:
  • not assigned
Biological process:
  • not assigned
Cellular component:
  • not assigned
Sequence domains:

Structure analysis Details

Assembly composition:
hetero trimer (preferred)
Assembly name:
PDBe Complex ID:
PDB-CPX-232132 (preferred)
Entry contents:
3 distinct polypeptide molecules
Macromolecules (3 distinct):
Antibody F2.I Fab, Light chain Chain: A
Molecule details ›
Chain: A
Length: 213 amino acids
Theoretical weight: 23.22 KDa
Source organism: Homo sapiens
Expression system: Homo sapiens
Structure domains: Immunoglobulins
Antibody F2.I Fab, Heavy chain Chain: B
Molecule details ›
Chain: B
Length: 221 amino acids
Theoretical weight: 23.32 KDa
Source organism: Homo sapiens
Expression system: Homo sapiens
Frizzled-5 Chain: C

Ligands and Environments

3 bound ligands:
Ligand EDO 13 x EDO
Ligand ACT 1 x ACT
Ligand NAG 1 x NAG
No modified residues

Experiments and Validation Details

wwPDB Validation report is not available for this entry.
X-ray source: CLSI BEAMLINE 08ID-1
Spacegroup: P6122
Unit cell:
a: 101.405Å b: 101.405Å c: 196.497Å
α: 90° β: 90° γ: 120°
R-values:
R R work R free
0.198 0.196 0.234
Expression system: Homo sapiens

Quick links

Citations

5 review citations

Aberrant WNT/CTNNB1 Signaling as a Therapeutic Target in Human Breast Cancer: Weighing the Evidence.
van Schie et al. (2020)
4 more

2 mentions without citation

Structure-guided design fine-tunes pharmacokinetics, tolerability, and antitumor profile of multispecific frizzled antibodies.
Raman et al. (2019)
1 more